CRISPR Therapeutics AG CRSP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/05/21 EST
115.15quote price arrow up+0.50 (+0.44%)
Volume
16,987
Close
114.65quote price arrow down-0.84 (-0.73%)
Volume
5,174,936
52 week range
32.30 - 220.20

...

Loading . . .

KEY STATS

  • Open115.86
  • Day High116.06
  • Day Low100.00
  • Prev Close115.49
  • 52 Week High220.20
  • 52 Week High Date01/15/21
  • 52 Week Low32.30
  • 52 Week Low Date03/16/20
  • Market Cap8.648B
  • Shares Out75.43M
  • 10 Day Average Volume2.42M
  • Dividend-
  • Dividend Yield-
  • Beta2.32
  • 1 Year % Change125.42

RATIOS/PROFITABILITY

  • EPS (TTM)-5.26
  • P/E (TTM)-21.79
  • Fwd P/E (NTM)-19.61
  • EBITDA (MRQ)-345.234M
  • ROE (MRQ)-26.80%
  • Revenue (MRQ)720,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-48,520.86%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date04/26/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

QUOTE FINDER

Profile

MORE
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including...
Rodger Novak M.D.
Chairman
Samarth Kulkarni Ph.D.
Chief Executive Officer
Lawrence Klein Ph.D.
Chief Operating Officer
Michael Tomsicek
Chief Financial Officer
Tony Ho M.D.
Executive Vice President
James Kasinger J.D.
General Counsel
Address
Baarerstrasse 14
Zug, ZUG
6300
Switzerland